Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly's Leap Tests Investors' Faith In Solanezumab

This article was originally published in Scrip

Executive Summary

Eli Lilly & Co. concedes that its revised primary endpoint for the ongoing Phase III clinical trial testing solanezumab in mild Alzheimer's patients goes against US FDA and European Medicines Agency (EMA) requirements, but the company is "hopeful" the change still will support regulatory approvals.

Advertisement

Related Content

Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?
Prothena CEO Dale Schenck Dies From Pancreatic Cancer
Lundbeck's Alzheimer's Strategy Targets Symptoms And Disease Modification
Lilly Executes Growth Strategy As New Products Drive Sales Gains
1Q Earnings Preview: What To Expect From US, EU Big Hitters

Topics

Advertisement
UsernamePublicRestriction

Register

SC064758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel